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Abstract 
The objective of the work presented here was to assess the feasibility of using glucosamine HCl as a 
solid-dispersion (SD) carrier to enhance the biopharmaceutical properties of a BCS class III/IV drug, 
acyclovir (ACV). The solid-dispersions of acyclovir and glucosamine HCl were prepared by an ethanol-
based solvent evaporation method. The prepared formulations characterized by photomicroscopy, 
scanning electron microscopy (SEM), differential scanning calorimetry (DSC), Fourier transforms infrared 
spectrophotometry (FTIR), powder x-ray diffractometry (PXRD) and drug content analysis. The functional 
characterization of ACV-SD was performed by aqueous solubility evaluation, dissolution studies, fasted 
versus fed state dissolution comparison, ex vivo permeability, and stability studies. Photomicroscopy and 
SEM analysis showed different surface morphologies for pure ACV, glucosamine HCl and ACV-SD. The 
physical-chemical characterization studies supported the formation of ACV-SD. A 12-fold enhancement in 
the aqueous solubility of ACV was observed in the prepared solid dispersions, compared to pure ACV. 
Results from in vitro dissolution demonstrated a significant increase in the rate and extent of ACV 
dissolution from the prepared ACV-SD formulations, compared to pure ACV. The rate and extent of ACV 
permeability across everted rat intestinal membrane were also found to be significantly increased in the 
ACV-SD formulations. Under fed conditions, the rate and extent of the in vitro dissolution of ACV from the 
formulation was appreciably greater compared to fasted conditions. Overall, the results from the study 
suggest the feasibility of utilizing glucosamine HCl as a solid dispersion carrier/excipient for 
enhancement of biopharmaceutical properties of acyclovir, and similar drugs with low solubility/
permeability characteristics. 
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ABSTRACT
The objective of  the work presented here was to assess the feasibility of  using glucosamine HCl as a solid-dispersion (SD) 
carrier to enhance the biopharmaceutical properties of  a BCS class III/IV drug, acyclovir (ACV). The solid-dispersions of  
acyclovir and glucosamine HCl were prepared by an ethanol-based solvent evaporation method. The prepared formulations 
characterized by photomicroscopy, scanning electron microscopy (SEM), differential scanning calorimetry (DSC), Fourier 
transforms infrared spectrophotometry (FTIR), powder x-ray diffractometry (PXRD) and drug content analysis. The 
functional characterization of  ACV-SD was performed by aqueous solubility evaluation, dissolution studies, fasted versus 
fed state dissolution comparison, ex vivo permeability, and stability studies. Photomicroscopy and SEM analysis showed 
different surface morphologies for pure ACV, glucosamine HCl and ACV-SD. The physical-chemical characterization studies 
supported the formation of  ACV-SD. A 12-fold enhancement in the aqueous solubility of  ACV was observed in the 
prepared solid dispersions, compared to pure ACV. Results from in vitro dissolution demonstrated a significant increase in 
the rate and extent of  ACV dissolution from the prepared ACV-SD formulations, compared to pure ACV. The rate and 
extent of  ACV permeability across everted rat intestinal membrane were also found to be significantly increased in the 
ACV-SD formulations. Under fed conditions, the rate and extent of  the in vitro dissolution of  ACV from the formulation 
was appreciably greater compared to fasted conditions. Overall, the results from the study suggest the feasibility of  utilizing 
glucosamine HCl as a solid dispersion carrier/excipient for enhancement of  biopharmaceutical properties of  acyclovir, and 
similar drugs with low solubility/permeability characteristics. 
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to fall into biopharmaceutics classification system’s 
(BCS) class II (↓ solubility, ↑ permeability), Class III 
(↑ solubility, ↓ permeability) or class IV (↓ solubility, ↓ 
permeability) (2). These drugs exhibit dissolution and/
or permeation rate-limited absorption. For these drugs, 
enhancement of  dissolution rate and/or permeability 
is vital to attain suitable blood concentration to 
achieve optimal bioavailability for therapeutic effect 
(3-5). Thus, for a formulation development team, 
there is a consistent and well-justified need to explore 
INTRODUCTION
Modern drug discovery techniques, which include high 
throughput screening and combinatorial chemistry, have 
generated new molecules with solubility characteristics 
that result in lower and inconsistent oral bioavailability 
(1). Over half  of  all newly discovered drugs appears 
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approaches that improve the dissolution and/or 
permeability characteristics of  such drugs.
Among the popular approaches explored in 
the past decade to achieve this goal include the 
micronization of  drugs, formulation of  drugs into 
liposomes, microspheres, microemulsions, inclusion 
complexes, nanoparticles, self-micro emulsifying 
drug delivery systems, solid dispersions, and other 
non-traditional drug delivery systems (6-14). Among 
these, formulating drugs into solid dispersions to 
improve their biopharmaceutical properties has gained 
widespread traction and acceptance. Solid dispersions 
are typically formed by uniformly dispersing one, or 
more, APIs into a hydrophilic matrix carrier using 
thermal, mechanical, co-solubilizing or a combination 
of  one or more similar techniques (15, 16). Within a 
solid dispersion, the solubility and permeability of  the 
API is reported to be improved by, a) the reduction 
of  particle size of  the drug to sub-micron or smaller, 
allowing increased surface area for dissolution, b) 
the alteration of  a crystalline drug to a high energy 
amorphous state, and c) increasing wettability of  the 
drug particles in an aqueous environment (16, 17). The 
development of  a successful solid dispersion often 
depends on the choice of  the carrier material, as well 
as, the processing method.
Acyclovir is an antiviral drug, commonly prescribed 
for the treatment of  infections caused by the herpes 
simplex viruses (HSV-1 and HSV-2) and the varicella-
zoster virus. Depending on the available strength of  the 
tablets, acyclovir has been classified as either a BCS class 
III or a class IV drug (18). Upon oral administration, 
acyclovir exhibits low oral bioavailability (~15-30%) 
(19). The low bioavailability of  acyclovir is attributed to 
its poor aqueous solubility, as well as, low permeability 
(20-23). Therefore, acyclovir was selected as a model 
drug for this study with the objective to improve its 
dissolution and permeability characteristics.
Glucosamine is a naturally occurring amino-
monosaccharide obtained from glucosamine-
6-phosphate via a hexosamine biosynthetic 
pathway. Structurally, it is a 2-amino-2-deoxy-β-D-
glucopyranose with the molecular formula (C6H13NO5). 
It is a non-toxic and a highly water-soluble (320 mg/
mL) compound (24, 25). Among its salts, that is 
hydrochloride (HCl), sulfate and N-acetyl, the HCl salt 
is pharmaceutically acceptable due to its high aqueous 
solubility and physical stability. The hydrophilic nature 
of  glucosamine HCl is reported to improve drugs with 
poor aqueous solubility and permeability by improving 
particle wettability in an aqueous environment (26). 
Despite its potential drug delivery optimizing benefits, 
the usage and applications of  glucosamine HCl as a 
carrier in the designing of  novel drug delivery systems 
remains largely unexplored. In recent years, only a few 
publications originating from the group of  Al-Hamidi 
et. al. have reported the potential for using glucosamine 
HCl as a solid dispersion carrier (26, 27). While useful 
and informative, these studies can be considered 
insufficient in terms of  material characterization and 
functional analysis of  the formulations.
Therefore this study describes a systematic and 
comprehensive feasibility analysis of  using glucosamine 
HCl as a solid dispersion carrier for improving the 
dissolution and/or permeability characteristics of  
acyclovir. For the study, acyclovir solid dispersion 
formulations (ACV-SD) with increasing ratios of  
glucosamine HCl were prepared using an ethanol-based, 
solvent-evaporation method. The prepared ACV-SD 
were subjected to physical-chemical characterization 
with scanning electron microscopy, particle size 
and zeta potential analysis, thermal analysis, Fourier 
transforms infrared spectroscopy, powder x-ray 
diffractometry, aqueous solubility, and drug content 
analysis. The ACV-SD were further characterized for 
their functionality via dissolution and permeability 
studies, and fasted- and fed- state dissolution studies. 
Finally, the influence of  controlled-storage conditions 
on the functional attributes of  ACV-SD was evaluated 
by conducting a preliminary stability study for a period 
of  six months. 
MATERIALS AND METHODS
Materials
Acyclovir was obtained from Zim Laboratories Ltd., 
Nagpur, India. D (+) Glucosamine hydrochloride was 
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Table 1 Composition of  the prepared acyclovir-glucosamine 
hydrochloride solid-dispersion formulations 






sourced from Sigma-Aldrich Corporation, St. Louis, 
MO, USA. Dichloromethane, ethanol, glacial acetic acid, 
soy lecithin, methanol, n-octanol, sodium hydroxide, 
and sodium taurocholate were acquired from Loba 
Chemical Pvt. Ltd., Mumbai, India. Calcium chloride, 
glucose, magnesium sulfate, potassium chloride, 
potassium dihydrogen phosphate, sodium chloride, 
and sodium bicarbonate were sourced from Merck 
Ltd. Mumbai, India. All other chemicals/solvents used 
were of  analytical grade and used as received.
Preparation of acyclovir solid dispersion (ACV-SD) 
Solid dispersions of  acyclovir (ACV-SD) using 
glucosamine HCl as a carrier were prepared using 
different drug:carrier ratios (1:1, 1:2, 1:3, 1:4, and 
1:5) according to the method previously described by 
Dhore et. al. (28). Briefly, acyclovir was weighed and 
dissolved in 10 mL ethanol. The ethanolic solution 
of  acyclovir was then added to previously weighed 
glucosamine HCl in a mortar and blended thoroughly. 
The blending/trituration was continued until the 
ethanol was completely evaporated, forming a uniform 
dispersion. Complete evaporation of  any residual 
ethanol was ensured by vacuum drying the samples at 
40°C for 12 hours. The dried ACV-SD sample powders 
were stored in amber glass vials (flushed with nitrogen) 
at controlled room temperature (25°C) until needed. 
The composition of  the prepared ACV-SD is shown 
in Table 1.
Physical-chemical characterization of ACV-SD
Photomicroscopy and scanning electron microscopy 
(SEM)
The preliminary microscopic assessment of  pure 
ACV, glucosamine HCl and the prepared ACV-SD 
was carried out using a digital microscope (Model: 
DM2500, Leica Microsystems, Germany). The samples 
for analysis were prepared by dispersing ~10 mg of  
either the drug, the carrier or the prepared formulation 
in 5 mL distilled water. A droplet from the uniformly 
mixed dispersion was then placed on a clean glass slide 
and observed under the microscope. The images of  
the samples were captured at different resolutions.
Additionally, individual samples were also examined for 
their surface characteristics using a scanning electron 
microscope (Model: Supra® 55, Carl Zeiss NTS Ltd., 
Germany). Briefly, the sample (~50g) was spread as a 
thin layer on a double-faced carbon tape, placed on 
the aluminum platform, which was then placed in the 
sample holder of  the microscope. The sample was 
then coated with a thin layer of  gold (~400 A°) using 
a sputter coater (Model: Supra® 55). The samples were 
scanned at an accelerating voltage of  10 kV, and the 
equipment-accompanied software (SmartSEM®, TV 
mode) was used to develop and record the images at 
different magnifications. 
 
Particle size and zeta potential analysis
The particle size distribution of  the prepared ACV-
SD was performed on a Photon Cross Correlation 
Spectrometer (Model: NANOPHOX Sympatec, 
GmbH, Clausthal-Zellerfeld, Germany) with dynamic 
light scattering using a procedure reported by our 
laboratory earlier (29). The test samples were prepared 
by dispersing ACV-SD in deionized water. The analysis 
was performed at an operating sensitivity of  1 nm to 
10 µm, and the particle count rate was optimized by 
the associated software.
 
The prepared ACV-SD were also analyzed for zeta 
potential using a Nano Particle Analyzer (Model: 
NanoPlusTM-2, Particulate system, Norcross, GA, 
USA). The analysis was carried out at a controlled 
temperature (25°C) and an operating range of  -200 to 
+200 mV.
Thermal analysis
To evaluate any interactions between ACV and 
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ACVcontent (%)= total ACV(mg)-freedrug (mg)
total ACV(mg)
= x 100 Eq. 1
glucosamine HCl, a differential scanning calorimeter 
(Model: Q20, TA Instrument, Inc., New Castle, DE, 
USA) was used to record the thermal behaviors of  
pure ACV, pure glucosamine HCl, the physical mixture 
(PM, 1:3) of  pure ACV and glucosamine HCl, and the 
prepared ACV-SD. Thermograms of  these samples 
were compared and analyzed. Individual samples (~ 2 
mg) were press-sealed in aluminum pans and analyzed 
on the equipment previously calibrated with an indium 
standard. Each sample was subjected to a heating 
cycle from 0°C to 400°C at a ramp rate of  10°C/min, 
under a continuous purge of  nitrogen (50 mL/min). 
The universal analysis software (Version 4.5A, build 
4.5.0.5, TA Instruments, Inc., New Castle, DE, USA) 
accompanied by the instrument was used to analyze 
and interpret the obtained thermograms. 
       
Fourier transforms infrared spectroscopy (FTIR) 
Pure ACV, glucosamine HCl, PM, and ACV-SD 
samples were subjected to FTIR analysis in an attempt 
to understand their chemical differences as well as any 
interactions between the ACV and glucosamine HCl, 
either in a physical mixture or within the prepared 
dispersion. The spectra were collected using an FTIR 
spectrophotometer (Model: FTIR-8300, Shimadzu, 
Kyoto, Japan) following the procedure reported by 
Telange et. al. (30), and compared in order to identify 
the occurrence of  any intermolecular interactions. 
Powder x-ray diffractometry (PXRD)
The crystal characteristics of  the drug, the carrier, 
their physical mixture (1:3), and the prepared 
solid dispersion were investigated by PXRD. The 
diffractograms were obtained on a bench-top x-ray 
diffractometer (MODEL: D8 ADVANCE, Bruker 
AXS, Inc., Madison, WI, USA), using the method 
reported previously by Telange et. al.  (29).
Estimation of ACV content in ACV-SD
The ACV content in the prepared ACV-SD was 
estimated spectrophotometrically, following a 
procedure described by Chaudhary et. al. (31). The 
appropriate quantity of  ACV-SD powder (containing 
~100 mg ACV) was dissolved in 100 mL phosphate 
buffer (0.05 M, pH 6.8). The resulting solution 
was filtered (membrane filter, 0.45 µm), and after 
relevant sequential dilutions, analyzed using a UV-
visible spectrophotometer (MODEL: V-630, JASCO 
International Co., Ltd., Tokyo, Japan) at 251 nm. The 
sample absorbance values were compared against 
those from a blank (a solution of  glucosamine HCl in 
phosphate buffer) to calculate the amount of  free ACV 
in the ACV-SD. The ACV content (%) incorporated 
in the prepared SD formulations was calculated using 
Equation 1.
Aqueous solubility analysis 
The aqueous solubilities of  pure ACV, ACV in the 
physical mixture, and ACV in the prepared dispersions 
were determined using a procedure mimicking the one 
described by Al-Hamidi et. al. (27). Excess amounts 
of  samples were individually dispersed in 10 mL 
distilled water in screw-cap glass vials and agitated on 
a rotary shaker (Model: RS-24 BL, REMI Laboratory 
Instruments, Remi House, Mumbai, India) at 37°C for 
24 hours. The dispersions were then filtered (0.45 µm), 
diluted, and the absorbance of  the resulting solutions 
was measured on a UV-visible spectrophotometer 
(MODEL: V-630, JASCO International Co., Ltd., 
Tokyo, Japan) at 251 nm. The absorbance values, after 
comparison with a blank and a standard solution of  
ACV, were used to calculate the aqueous solubility of  
ACV.
Functional characterization of ACV-SD
In vitro dissolution studies
Comparative assessment of  the release pattern of  
pure ACV and ACV from ACV-SD was performed 
using a USP Type II (paddle) dissolution equipment 
(Model: TDT-08LX, Electrolab India Pvt. Ltd., 
Mumbai, India). Each dissolution run was conducted 
by dispersing pure ACV (40 mg) or ACV-SD (~40 
mg ACV) in the dissolution vessel containing freshly 
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prepared phosphate buffer (900 mL, 0.05 N, pH 6.8) 
maintained at 37°C. The experiment was carried out 
for 120 minutes at 100 RPM stirring speed. Sample 
aliquots for testing were collected at 10 minute intervals 
and replaced with equal volumes of  fresh medium. 
The test samples, after filtration and appropriate 
dilutions, were measured for absorbance using a UV-
visible spectrophotometer (MODEL: V-630, JASCO 
International Co., Ltd., Tokyo, Japan) at 251 nm. The 
absorbance values, after comparison with a blank and 
a standard solution of  ACV, were used to calculate the 
cumulative dissolution profiles of  ACV and ACV-SD.
                                                                                      
Influence of fasted versus fed-state media
The influence of  fasted versus fed state on the dissolution 
behavior of  pure ACV and ACV-SD was assessed by 
conducting dissolution tests using standard Fasted 
(FaSSIF) and Fed-state (FeSSIF) dissolution media. 
The media were prepared using the procedure reported 
by Klein et. al. (32). The dissolution was performed 
on a USP Type II (paddle) dissolution test apparatus 
(Model: TDT-08LX, Electrolab India Pvt. Ltd., 
Mumbai, India). Each dissolution run was conducted 
by dispersing pure ACV (100 mg) or ACV-SD (~100 
mg ACV) in the dissolution vessel containing either 
FaSSIF (500 mL) or FeSSIF (1000 mL) maintained at 
37°C. The dissolution was carried out for 120 min at a 
paddle stirring speed of  50 RPM. Aliquots of  samples 
were collected at 10 minute intervals for testing and 
replaced with an equal volume of  the blank medium. 
The test samples, after filtration and appropriate 
dilutions, were measured for absorbance on a UV-
visible spectrophotometer (Model: V-630, JASCO 
International Co., Ltd., Tokyo, Japan) at 248.2 nm 
(FaSSIF) or 272 nm (FeSSIF). The absorbance values 
were used to calculate the cumulative dissolution 
profiles of  ACV and ACV-SD in respective media.
       
Permeability across a biological membrane
The biological permeability of  pure ACV and ACV in 
the prepared dispersion was assessed using the everted 
rat intestine method previously reported by Dixit et. al. 
(33). The details of  the method, including the design 
and assembly of  the apparatus, the use of  experimental 
animals, and so on has been reported previously and 
followed as described therein (34). Briefly, the isolated 
intestinal membrane was mounted on the apparatus 
filled with Krebs solution (250 mL) as a permeation 
medium. The test sample solutions i.e., pure ACV 
(100 µg/mL) or ACV-SD (~100 µg/mL), prepared 
using Krebs solution, were placed in the apparatus on 
the mucosal side of  the membrane. The medium was 
maintained at 37°C and continuously stirred at 25 RPM 
for a period of  120 minutes. Aliquots of  samples were 
withdrawn at regular intervals from the serosal side 
of  the membrane, and after filtration and appropriate 
dilutions, were measured for absorbance using a UV-
visible spectrophotometer (MODEL: V-630, JASCO 
International Co., Ltd., Tokyo, Japan) at 250.4 nm. The 
obtained absorbance values were used to calculate the 
cumulative permeability profiles of  ACV and ACV-SD.
    
Preliminary stability assessment  
The optimized ACV-SD formulation i.e., ACV-SD3 
was evaluated for its functional stability upon storage 
under controlled storage conditions (25°C at 60% 
RH). The samples were packaged in screw-capped, 
high-density polyethylene (HDPE), amber-colored 
bottles, and stored in an environmental chamber 
(Model: TS00002009, Mumbai, Maharashtra, India) for 
a period of  six months. At the end of  six months, the 
samples were retrieved and subjected to dissolution and 
permeability studies using the respective procedures 
described above.
Statistical analysis
The results are presented as mean ± standard deviation. 
The statistical analysis for comparing differences 
between test samples was performed using a one-way 
analysis of  variance (ANOVA) followed by a Dunnett’s 
or a Students t-test. P values of  ≤ 0.05 were considered 
as a statistically significant difference.
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Figure 1 Photomicroscopy images of  (A) pure acyclovir, (B) pure glucosamine HCl, and (C) acyclovir-glucosamine HCl solid dispersion. 
Scanning electron microscopy images of  (a) pure acyclovir, (b) pure glucosamine HCl, and (c) acyclovir-glucosamine HCl solid dispersion 
(ACV-SD).
RESULTS AND DISCUSSION
Physical-chemical characterization of ACV-SD
Photomicroscopy and scanning electron microscopy 
(SEM)  
Microscopic images of  pure ACV, pure glucosamine 
HCl, and ACV-SD, captured at 20X magnification are 
shown in Figure 1 (A, B, and C). Pure ACV (Figure 1A) 
appeared as small, regular crystals with well-defined 
geometric faces and edges. The morphology of  these 
crystals appeared to correspond to the monoclinic 
polymorphic form V of  ACV (35). The glucosamine 
HCl particles (Figure 1B) appeared to be relatively 
larger, globular particles with a smooth surface. 
The particles of  ACV-SD (Figure 1C) appeared as 
non-uniform, clusters with ill-defined morphology. 
The defining characteristics of  pure ACV or pure 
glucosamine HCl were absent in ACV-SD.
Further analysis of  these particles using SEM 
imaging confirmed the observations from the photo-
microscopic images (Figure 1a, 1b, and 1c). Pure ACV 
exhibited a crystalline, regular structure with geometric 
angles (Figure 1a). Pure glucosamine HCL showed 
larger particles with a rounded, smooth surface. The 
ACV-SD particles appeared as irregular clusters/
aggregates formed as a result of  the physical interaction 
between ACV and glucosamine HCl.
Particle size and zeta potential analysis
The mean particle size and zeta potential are 
considered relevant markers indicative of  the physical 
stability of  sub-micron particles dispersed in a liquid 
medium (29). Particles sizes  ≤ 500 nm are known to 
prefer endocytosis as a major pathway of  transport 
across biological membranes (36). The mean particle 
size of  the prepared ACV-SD was  ~120 nm with a 
polydispersity index (PDI) of  31.06 (Figure 2A). The 
This Journal is © IPEC-Americas September 2019 J. Excipients and Food Chem. 10 (3) 2019 71
Original Article
Figure 2 Particle size distribution (A) and zeta potential (B) of  the prepared ACV-SD formulation.
prepared formulation thus has a sub-micron particle 
size and a narrow distribution.
Zeta potential (ζ) often indicates the relative physical 
stability of  multiparticulate, disperse systems. The 
measured zeta potential value of  the prepared ACV-
SD formulation was – 39.43 ± 0.23 mV (Figure 2B), 
indicating that the prepared formulation dispersion 




Physical interactions, if  any, between the components 
of  a formulation, are generally quite conveniently 
assessed using comparative thermal analysis. Such 
interactions are generally revealed in the form of  
appearance, disappearance, shifting, or changes 
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Figure 3 DSC thermograms of  (A) pure ACV, (B) pure glucosamine HCl, (C) the physical mixture (1:3) of  ACV and glucosamine HCl, 
and (D) the prepared ACV-SD formulation.
the melting temperature of  ACV. Another minor 
endothermic event was observed for pure ACV between 
~60°C and ~ 175°C (not apparent in the figure). This 
event may be attributed to the phase transition of  
polymorphic hydrate form V to anhydrous form III 
in the range of  65°C and 100°C, and thereafter from 
form III to anhydrous form VI at higher temperatures. 
These changes in the thermal characteristics of  ACV 
are not uncommon and have been reported earlier (9, 
10, 37). The thermogram of  glucosamine HCl (Figure 
3B) revealed two, broad, fused endothermic peaks; a 
larger peak with an onset at ~190°C and a smaller peak 
in the onset and/or relative areas of  the peaks as a 
function of  controlled temperature increases. These 
interactions may indicate melting, degradation, and/
or incompatibilities between the components of  the 
formulation.
 
Figure 3 (A, B, C, and D) shows the thermograms 
obtained from the DSC analysis of  pure ACV, pure 
glucosamine HCl, the physical mixture (PM, 1:3) of  
pure ACV and glucosamine HCl, and the prepared 
ACV-SD. The thermogram of  pure ACV (Figure 
3A) exhibited a sharp peak at ~256°C, indicative of  
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Figure 4 FTIR spectra of  (A) pure ACV, (B) pure glucosamine HCl, (C) the physical mixture (1:3) of  ACV and glucosamine HCl, and 
(D) the prepared ACV-SD formulation.
The spectra obtained from the infrared analysis of  
pure ACV, pure glucosamine HCl, the physical mixture 
(PM, 1:3) of  pure ACV and glucosamine HCl, and 
the prepared ACV-SD are shown in Figure 4A, 4B, 
4C, and 4D, respectively. For pure ACV (Figure 4A), 
characteristic absorption bands were located at ~3622 
cm-1 (primary amine) and 3411 cm-1 (secondary amine, 
N-H stretching). Additional peaks typically associated 
with ACV were found at ~1712 cm-1 (C=O stretching), 
~1630 cm-1 and ~1609 cm-1 (amine), ~1483 cm-1 (O-H 
stretching), and ~1347 cm-1 (C-H stretching). These 
observations were consistent with previous findings 
(10, 38). The FTIR spectrum of  glucosamine HCl 
(Figure 4B) exhibited a characteristic absorption peak 
at ~3291 cm-1 (N-H and O-H stretching). Other peaks 
related to glucosamine were observed at ~3000 cm-1 
and 2881 cm-1 (-C-H stretching), ~1618 cm-1 and 
1537 cm-1 (N-H bending), ~1140 cm-1 (asymmetric 
at ~229°C. The first peak is likely associated with the 
melting of  glucosamine HCl, and the second, smaller 
peak may be associated with its degradation. These 
results are in agreement with previously published 
reports (26, 27). The thermograms of  the physical 
mixture (Figure 3C) exhibited broad, fused peaks 
similar to that of  pure glucosamine HCl, along with the 
disappearance of  the melting peak of  ACV. It is likely 
that with increasing temperatures, glucosamine HCl 
melted earlier at around 190°C and ACV dispersed/
dissolved in the carrier matrix in situ.  The thermogram 
of  ACV-SD (Figure 3D) revealed broad, diffused 
endothermic peaks that were uncharacteristic of  either 
pure ACV or pure glucosamine HCl. The absence of  
defining peaks of  ACV and glucosamine HCl in ACV-
SD thermogram is expected to owe the possibility that 
ACV is molecularly dispersed into the carrier matrix, 
resulting in partial amorphization of  ACV.
Fourier transform infrared spectroscopy (FTIR) 
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Figure 5 The x-ray diffractograms of  (A) pure ACV, (B) pure glucosamine HCl, (C) the physical mixture (1:3) of  ACV and glucosamine 
HCl, and (D) the prepared ACV-SD formulation.
C-O-C stretching) and ~1094 cm-1 (C-O functional 
group). These results were analogous to those reported 
earlier (39). The spectrum of  the physical mixture of  
the drug and the carrier (Figure 4C) showed peaks 
corresponding mostly to glucosamine HCl, albeit with 
higher absorbance intensities. The higher ratio of  
glucosamine HCl in the mixture can be attributed to 
the observed predominance of  glucosamine related 
peaks. The FTIR plot of  ACV-SD formulation (Figure 
4D) was found to be significantly different compared to 
those of  the individual components. The characteristic 
peaks associated with pure ACV and pure glucosamine 
HCl were absent in this spectrum. Several absorption 
peaks were observed in the region between 3300 cm-1 
and 1085 cm-1. The presence of  unique peaks in this 
spectrum can be likely attributed to hydrogen bonding 
between the N-H functional group of  ACV and the 
O-H group of  glucosamine HCl, and the formation 
of  solid dispersion (10, 27). The formation of  solid 
dispersion not only helps in solubilizing the API into 
the hydrophilic carrier but also likely prevents the 
recrystallization of  the drug in the glass solution (40).
Powder x-ray diffractometry (PXRD)
Powder x-ray diffractometry (PXRD) provides 
useful information on the crystalline properties and 
any polymorphic changes in the components of  a 
formulation. The diffractograms obtained from the 
PXRD analysis of  pure ACV, pure glucosamine HCl, 
the physical mixture (PM, 1:3) of  pure ACV and 
glucosamine HCl, and the prepared ACV-SD are shown 
in Figure 5 (A, B, C and D). The diffractogram of  pure 
ACV (Figure 5A) showed a sharp, high-intensity peak 
at ~7° 2θ, related to ACV crystal structure. Other low-
intensity peaks were observed at ~ 10.5°, 21°, 26°, and 
29° on the 2θ scale. All these peaks are associated with 
the polymorphic form V of  ACV and in agreement with 
earlier published reports (10). The diffraction pattern 
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Table 2 Drug content of  acyclovir in prepared solid-dispersion 
formulations
FORMULATION DRUG CONTENT (%, w/w)*
ACV-SD1 95.30 ± 0.65
ACV-SD2 97.21 ± 1.32
ACV-SD3 98.17 ± 0.49
ACV-SD4 96.10 ± 1.01
ACV-SD5 96.44 ± 1.20
*All results are expressed as mean ± Std. Dev., n=3
Table 3 Aqueous solubility of  pure acyclovir, acyclovir in physical 
mixture (PM), and acyclovir in the prepared solid-dispersions
FORMULATION AQUEOUS SOLUBILITY  (μg/mL)*
Pure acyclovir 13.91 ± 0.02
PM-1 82.25 ± 0.03
PM-2 84.59 ± 0.02
PM-3 85.11 ± 0.08
PM-4 83.27 ± 0.04
PM-5 84.40 ± 0.03
ACV-SD1 165.15 ± 0.02
ACV-SD2 171.28 ± 0.08
ACV-SD3 191.33 ± 0.06 
ACV-SD4 183.49 ± 0.06
ACV-SD5 180.36 ± 0.07
*All results are expressed as mean ± Std. Dev., n=3
of  glucosamine HCl (Figure 5B) exhibited several low 
and high-intensity peaks in the region between 12° 
2θ and 60° 2θ, along with a partial amorphous ‘halo’ 
pattern between 5° 2θ and 15° 2θ, indicating a mostly 
crystalline nature of  the carrier. The diffractogram was 
similar to that reported previously in the literature (26). 
The diffractogram of  the physical mixture (Figure 5C) 
showed a series of  peaks between 7° 2θ and 43° 2θ. 
These peaks appeared to those observed with pure 
ACV and pure glucosamine HCl, albeit with lower 
intensities for peaks associated with ACV. Finally, 
the diffractogram of  ACV-SD revealed peaks that 
were of  significantly lower in number and intensities 
compared to the pure components (Figure 5D). The 
diffractogram appeared to retain the characteristic 
peaks of  the carrier, whereas, ACV-related peaks were 
greatly minimized. It is likely that ACV is partially 
amorphized in the prepared solid dispersion.
Estimation of  the ACV content in ACV-SD
The ACV content in the prepared ACV-SD is 
represented as % ACV incorporated in Table 2. For 
all ACV-SD formulations, the ACV content was found 
to be > 95% w/w. The formulation ACV-SD3 (drug-
carrier ratio of  1:3) showed the highest incorporation 
efficiency (98.17 ± 0.49 %) and was used as an optimal 
formulation for most of  the characterization studies. 
The high incorporation efficiency of  ACV in the 
prepared formulation supported the selection of  carrier 
and the robustness of  the formulation approach.
Aqueous solubility analysis
The results obtained from the aqueous solubility 
analysis of  pure ACV, the physical mixtures of  ACV 
and glucosamine HCl, and the prepared ACV-SD 
formulations are presented in Table 3. Pure ACV 
exhibited aqueous solubility of  ~14 µg/mL. This is 
not surprising, as ACV is a known BCS Class III (↑ 
solubility, ↓ permeability) or class IV (↓ solubility, ↓ 
permeability) drug (18). The results are in agreement 
with previously published aqueous solubility values for 
ACV (9, 41). The solubilities of  ACV in the physical 
mixtures ranged between 82 and 85 µg/mL. These 
values represented a nearly 6-fold higher solubility 
of  ACV in the physical mixture compared to that of  
ACV alone. A close association of  the water-soluble 
carrier resulting in an increased wetting efficiency of  
ACV particles in the aqueous medium is a likely cause 
for the observed higher aqueous solubility of  ACV in 
the physical mixture. Among the physical mixtures, 
ACV-SD3 (drug-carrier ratio of  1:3) exhibited the 
highest observed solubility of  ACV. Further increase 
in the ratio of  carrier probably restricted ACV particles 
access to water, resulting in the observed modest 
decrease in ACV solubility (27). The prepared ACV-SD 
formulations exhibited significantly higher solubilities 
of  ACV, compared to that of  pure ACV or ACV in 
the physical mixtures. The solubilities of  ACV in these 
formulations ranged between 165 and 191 µg/mL. 
These results represented a nearly 12-fold increase in 
the solubility of  ACV compared to that of  ACV alone, 
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Figure 6 The comparative in vitro dissolution profiles of  ACV and ACV-SD3 formulations.
and a 2-fold increase compared to that of  ACV in the 
physical mixture. The solubilities of  ACV within these 
formulations followed a trend similar to that observed 
with the physical mixtures. The observed enhanced 
aqueous solubility of  ACV in these formulations may 
be attributed to carrier-assisted modifications of  the 
physical-chemical properties of  ACV such as changes 
in the particle size, morphology, and polymorphic state 
(26).
Functional characterization of ACV-SD
In vitro dissolution studies
The comparative dissolution profiles of  pure ACV and 
the ACV-SD formulations prepared using different 
drug-carrier ratios, in phosphate buffer (0.05 M, pH 
6.8) are represented in Figure 6. Pure ACV exhibited 
an initial rapid dissolution (~30% in 10 minutes), 
followed by a steady, zero-order release over a period 
of  2 hours. At the end of  the dissolution period, the 
extent of  cumulative ACV dissolution was recorded at 
~62%. The relatively lower dissolution efficiency of  
pure ACV is attributable to its low aqueous solubility. 
The rate and extent of  ACV dissolution from the 
prepared ACV-SD formulations followed the trend 
observed with the solubility studies, i.e., cumulative 
rate and extent of  ACV dissolution increased in 
formulations with increasing drug-carrier ratio, up to 
the ratio of  1:3. For formulations with a drug-carrier 
ratio of  1:4 and 1:5 the cumulative dissolution of  ACV 
was observed to be relatively slower and to a lesser 
extent. This is possibly due to the higher concentration 
of  carrier inhibiting the access of  ACV particles to the 
dissolution media (27). ACV-SD3 (drug-carrier ratio of  
1:3) exhibited the highest observed rate and extent of  
ACV dissolution (~94%). Earlier studies suggested that 
solvent-evaporation-method-based solid dispersions 
produce high energy solid-state formulations by partial 
amorphization of  drug particles, which increases the 
dissolution rate of  drugs (17). Another possibility for 
explaining enhanced aqueous solubility may be the 
hydrophilic nature of  glucosamine HCl increasing the 
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Figure 7 The influence of  fasted and fed-state conditions on the dissolution behavior of  pure ACV and the ACV-SD formulations.
wettability of  dispersed ACV particles in ACV-SD (26).
Influence of fasted versus fed state media
Figure 7 shows a comparison of  the dissolution 
profiles of  pure ACV and that of  ACV from ACV-
SD3 formulation as tested in FaSSIF (fasted) and 
FeSSIF (fed) media. The efficiency of  the dissolution 
of  pure ACV was found to be lower in fasted 
conditions compared to that in fed conditions. At 
the end of  the 2-hour dissolution period, only about 
43% of  pure ACV had dissolved. In fed conditions, 
there was a modest, albeit significant increase in the 
efficiency of  ACV dissolution (~64% at the end of  
2 hours). Positive food effects on the dissolution of  
drugs with low aqueous solubility have been reported 
earlier (32, 42). The rate and extent of  ACV release 
from ACV-SD3 were found to be higher in both fasted 
and fed conditions compared to that of  pure ACV. In 
fasted conditions ~76%, and in fed conditions ~84% 
ACV was released at the end of  the 2-hour dissolution 
period. These results correlated well with those 
obtained from the solubility analysis and the in vitro 
dissolution studies.
Permeability across a biological membrane
The comparative permeabilities of  pure ACV and 
ACV-SD formulations across a biological membrane, 
as evaluated by the everted rat intestine model are 
shown in Figure 8. After the 2-hour testing period, 
only about 42% of  pure ACV had permeated across 
the membrane. ACV is reported at a BCS class III or 
IV drug (low permeability), and thus the results are 
consistent with those published previously (8, 18). 
The permeability profiles of  ACV from all ACV-
SD formulations were found to be relatively higher 
compared to that of  pure ACV. The permeability 
of  ACV from these formulations followed the trend 
observed with the results obtained from solubility 
and dissolution studies. In general, the rate and 
extent of  ACV permeability increased with increasing 
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Figure 8 The comparative ex vivo permeability profiles of  the ACV and ACV-SD formulations.
drug-polymer ratio up to 1:3. ACV permeability was 
observed to be lower for formulations with a drug-
carrier ratio of  1:4 and 1:5. ACV-SD3 (drug-carrier 
ratio of  1:3) exhibited the highest observed efficiency 
of  ACV permeability.
Preliminary stability assessment  
The results obtained from the preliminary stability 
assessment of  the selected ACV-SD3 formulation was 
stored at controlled temperature (25°C) and relative 
humidity (60 ± 5% RH) for 6 months are shown in 
Figure 9. Figure 9A shows a comparison of  dissolution 
profiles of  ACV-SD3 at day 0 and day 180 (6 months). 
It was observed that while the drug release from the 
180-day sample followed a pattern similar to that 
of  day 0 sample, there was a noticeable decrease in 
the efficiency of  ACV dissolution at the end of  
the duration of  the study. Figure 9B compares the 
permeability profiles of  ACV-SD3 at day 0 and day 180. 
Similar to the dissolution results, there was a noticeable 
decrease in the efficiency of  ACV permeability for the 
samples stored for 180 days, whilst the permeability 
profile followed matching patterns. The reasons for 
this shift in the dissolution and permeability of  ACV-
SD are currently unclear. It is possible that the storage 
conditions, mainly the relative humidity have had an 
influence on the physical-chemical properties of  ACV 
or the solid dispersion. Further characterization of  the 
stored samples is currently underway.
CONCLUSIONS
The present study aimed to study the feasibility of  
utilizing a relatively unexplored, hydrophilic excipient, 
glucosamine HCl as a solid-dispersion carrier with the 
goal of  enhancing the biopharmaceutical properties 
of  drugs with low aqueous solubility. Solid dispersion 
based formulations of  acyclovir combined with 
glucosamine HCl were successfully prepared using a 
previously established solvent-evaporation method. 
The prepared formulations were characterized for 
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Figure 9 The effect of  controlled storage conditions (25°C/60% RH, 180 days) on (A) dissolution and (B) permeability of  ACV-
SD3.
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their physical and functional properties using various 
analytical methods. The prepared ACV-glucosamine 
HCl solid dispersions demonstrated marked increases 
in aqueous solubility, dissolution, and permeability of  
acyclovir compared to the pure drug. The prepared 
solid dispersions were not found to be drastically 
unstable, the storage conditions appeared to have a 
modest influence on the physical-chemical properties 
of  either the drug or the formulation. While the nature 
of  this influence is unclear, further characterization 
of  the stored samples is warranted. The study overall 
demonstrates the feasibility of  utilizing glucosamine 
HCl as a potential solid-dispersion carrier to improve 
the biopharmaceutical properties of  drugs with low 
solubility and/permeability characteristics. 
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